A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)

著者: R.E. O'Cearbhaill, J.H. Park, Elizabeth Halton, Claudia Diamonte, Edward A. Mead, Yuliya Lakhman, Peter E. Kane, Isabelle Rivière, Renier J. Brentjens - Gynecologic Oncology 2020 被引用: 35